A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
Keywords: Mycobacterium ulcerans; Q203; Telacebec; bedaquiline; bioenergetics; cytochrome bcc-aa3; oxidative phosphorylation; terminal oxidase; tuberculosis.
Copyright © 2020 American Society for Microbiology.